Bicycle Therapeutics, a biotech firm pioneering a new therapeutic class based on its patented bicyclic peptide or Bicycle® platform, and Oxurion have recently declared complete registration of Oxurion’s Phase I clinical trial planned to assess the safety of THR-149’s single injection. The injection essentially is a new Bicycle-based plasma kallikrein suppressor.

According to a press release by the Bicycle Therapeutics, the agreement states that Oxurion has exclusive authority to conduct clinical and preclinical development, as well as commercialization of a designated medicine candidate. In return, Bicycle would attain milestone payments for development and royalties on sales of products resulting from the association.

Bicycle provides a differentiated method to a variety of debilitating ailments, and the company is pleased to view the growth Oxurion has attained in successfully finishing the registration of the Phase I study of the first Bicycle-based therapeutic, stated Kevin Lee, Ph.D., CEO Bicycle Therapeutics.

THR-149, in consort with Bicycle-owned BT1718, Bicycle Toxin Conjugate for oncology, represents the first of many initiatives the firm is proceeding with to bring this exceptional therapeutic modality to patients with significant unfulfilled medical needs, Lee added.

Patrik De Haes, M.D. & CEO of Oxurion, reportedly stated that patients suffering from diabetic macular edema have higher levels of PKal. Our aim in the current Phase I clinical trial is to assess the safety of a single THR-149 intravitreal injection, a new Bicycle-based PKal suppressor, in patients having visual impairment because of diabetic macular edema, Haes stated. Enrolling subjects is the first step to assessing whether we can constrain PKal with Bicycle’s new bicyclic peptides, he added.

For the record, Bicycle Therapeutics is a clinical-phase biopharmaceutical firm developing a new class of pills, termed as Bicycles, for illnesses that are underserved by currently available therapeutics. It was founded in 2009, resulting from an innovative science performed by Professor Christian Heinis and Sir Greg Winter.

Source Credits: https://www.apnews.com/Business%20Wire/2aec99859114480da690c30619ccc460